105 gene panel by DNA sequencing
When limited tissue is available When tumor tissue is insufficient for sequencing, the Tempus xF liquid biopsy assay may be used to assess cfDNA from a peripheral blood draw, providing a genomic result.
- For use in patients with tumors that have limited tissue available for sequencing
- Also useful for patients unable to undergo additional tissue collection procedures Monitor
mechanisms of resistance Recently published data has identified multiple resistance mechanisms that arise from frontline targeted therapies in patients with advanced cancer, such as:
- EGFR & ALK resistance mutations in lung cancer
- ESR1 mutations in breast cancer
- BRCA1/2 reversion alterations in ovarian and breast cancer
- Anti-EGFR resistance mechanisms in colorectal cancer
Simultaneous Tissue and Liquid Biopsy Testing
Data suggests that non-overlapping actionable gene alterations and resistance mechanisms may be detected using concurrent tissue and liquid biopsy testing.
In a recent analysis, 9% of patients with four common cancer types had unique actionable variants found in liquid biopsy that were not detected in solid tumor alone
xF Gene Panel
AKT1 AKT2 ALK APC AR ARAF ARID1A ATM ATR B2M BAP1 BRAF BRCA1 BRCA2 BTK CCND1 CCND2 CCND3 CCNE1 CD274 (PD-L1) CDH1 CDK4 CDK6 CDKN2A CTNNB1 DDR2 DPYD EGFR ERBB2 (HER2) ERRFI1 ESR1 EZH2 FBXW7 FGFR1 FGFR2 FGFR3 FGFR4 FLT3 FOXL2 GATA3 GNA11 GNAQ GNAS HNF1A HRAS IDH1 IDH2 JAK1 JAK2 JAK3 KDR KEAP1 KIT KMT2A KRAS MAP2K1 MAP2K2 MAPK1 MET MLH1 MPL MSH2 MSH3 MSH6 MTOR MYC MYCN NF1 NF2 NFE2L2 NOTCH1 NPM1 NRAS NTRK1 PALB2 PBRM1 PDCD1LG2 PDGFRA PDGFRB PIK3CA PIK3R1 PMS2 PTCH1 PTEN PTPN11 RAD51C RAF1 RB1 RET RHEB RHOA RIT1 RNF43 ROS1 SDHA SMAD4 SMO SPOP STK11 TERT TP53 TSC1 TSC2 UGT1A1 VHL
xF Specimen Requirements
Peripheral blood 2 x 8.5ml Streck tubes filled with peripheral blood Streck tubes for xF are stable for 5 days from the date of collection; must be received at Tempus within that time frame